Health Professional's Exposure, Attitude, and Acceptance of Drug Promotion by Industry Representatives: A Cross-sectional Study in Ethiopia

Overview

Journal Sci Prog

Publisher Sage Publications

Specialty Science

Date 2021 Jun 30

PMID 34191639

Citations 2

Authors

Dawit Kumilachew Yimenu

Chilot Abiyu Demeke

Asmamaw Emagn Kasahun

Ebrahim Abdela Siraj

Adane Yehualaw Wendalem

Zegaye Agmassie Bazezew

Berhanemeskel Weldegerima Atsbeha

Abebe Basazn Mekuria

Affiliations

Soon will be listed here.

Abstract

Interactions between pharmaceutical companies and health care providers have long been an area of interest from ethical as well as scientific grounds. The information provided by those companies must be scientifically accurate and fair. The current study aimed to investigate the exposure, attitude, and training background of medical doctors and pharmacy professionals regarding drug promotional activities, and assess their acceptance of promotional gifts provided by pharmaceutical sales representatives. A cross-sectional study was conducted on medical doctors and pharmacy professionals working at Bahir Dar and Gondar cities, Amhara regional state, Ethiopia. Data were collected using a self-administered structured questionnaire and Statistical Package for Social Science (SPSS) version 26 was used for analysis. A Chi-square test was computed to investigate the presence of an association between the dependent and independent variables. A -value of less than 0.05 was considered to declare significance at a 95% Confidence Interval (CI). A total of 105 health professionals, 81 pharmacy professionals, and 24 medical doctors have participated in the study. Above two-thirds of the respondents (69.5%) agreed that most talks sponsored by drug companies were helpful and educational. On the other hand, 39% of the respondents agreed and 47.6% disagreed that receiving gifts from pharmaceutical representatives will increase the chance that they will eventually sell or recommend the drug company's products. The majority of the study participants (81%) preferred drug samples and stationery as appropriate gifts by pharmaceutical sales representatives. Significant gaps were found regarding the training of health professionals about the ethics of drug marketing and how to deal with pharmaceutical representatives. Policies aiming at restricting health care provider's contacts with pharmaceutical companies during residency training along with incorporating gift restriction policies could bring significant improvements.

Citing Articles

A descriptive survey of specialty pharmacy team members' perceptions of interactions with field representatives from pharmaceutical companies.

Wang E, Lee L, Lee Y, Mullen M, Hill A, Rotolo S J Manag Care Spec Pharm. 2023; 29(10):1151-1157.

PMID: 37776117 PMC: 10541627. DOI: 10.18553/jmcp.2023.29.10.1151.

Attitude and perception of pharmacists and healthcare professionals about the criteria used in drug formulary selection in the United Arab Emirates.

Al-Hemyari S, Mohamed Noor D, El-Dahiyat F J Pharm Policy Pract. 2022; 15(1):67.

PMID: 36258258 PMC: 9580123. DOI: 10.1186/s40545-022-00460-w.

References

Zaki N . Pharmacists' and physicians' perception and exposure to drug promotion: A Saudi study. Saudi Pharm J. 2015; 22(6):528-36. PMC: 4281594. DOI: 10.1016/j.jsps.2014.02.008. View

Prosser H, Walley T . Understanding why GPs see pharmaceutical representatives: a qualitative interview study. Br J Gen Pract. 2003; 53(489):305-11. PMC: 1314573. View

Green M, Masters R, James B, Simmons B, Lehman E . Do gifts from the pharmaceutical industry affect trust in physicians?. Fam Med. 2012; 44(5):325-31. View

Fischer M, Keough M, Baril J, Saccoccio L, Mazor K, Ladd E . Prescribers and pharmaceutical representatives: why are we still meeting?. J Gen Intern Med. 2009; 24(7):795-801. PMC: 2695530. DOI: 10.1007/s11606-009-0989-6. View

Lieb K, Scheurich A . Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One. 2014; 9(10):e110130. PMC: 4199668. DOI: 10.1371/journal.pone.0110130. View

Chew L, OYoung T, Hazlet T, Bradley K, Maynard C, Lessler D . A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000; 15(7):478-83. PMC: 1495488. DOI: 10.1046/j.1525-1497.2000.08014.x. View

Chren M, Landefeld C . Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271(9):684-9. View

Farthing-Papineau E, Peak A . Pharmacists' perceptions of the pharmaceutical industry. Am J Health Syst Pharm. 2005; 62(22):2401-9. DOI: 10.2146/ajhp050073. View

Brennan T, Rothman D, Blank L, Blumenthal D, Chimonas S, Cohen J . Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295(4):429-33. DOI: 10.1001/jama.295.4.429. View

10.

Grande D, Shea J, Armstrong K . Pharmaceutical industry gifts to physicians: patient beliefs and trust in physicians and the health care system. J Gen Intern Med. 2011; 27(3):274-9. PMC: 3286560. DOI: 10.1007/s11606-011-1760-3. View

11.

Schwartz L, Woloshin S . Medical Marketing in the United States, 1997-2016. JAMA. 2019; 321(1):80-96. DOI: 10.1001/jama.2018.19320. View

12.

Mintzes B, Lexchin J, Sutherland J, Beaulieu M, Wilkes M, Durrieu G . Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013; 28(10):1368-75. PMC: 3785667. DOI: 10.1007/s11606-013-2411-7. View

13.

McCormick B, Tomlinson G, Brill-Edwards P, Detsky A . Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA. 2001; 286(16):1994-9. DOI: 10.1001/jama.286.16.1994. View

14.

Campbell E, Gruen R, Mountford J, Miller L, Cleary P, Blumenthal D . A national survey of physician-industry relationships. N Engl J Med. 2007; 356(17):1742-50. DOI: 10.1056/NEJMsa064508. View

15.

Francer J, Izquierdo J, Music T, Narsai K, Nikidis C, Simmonds H . Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Med. 2014; 9:7. PMC: 3974225. DOI: 10.1186/1747-5341-9-7. View

16.

Workneh B, Gebrehiwot M, Bayo T, Gidey M, Belay Y, Tesfaye D . Influence of Medical Representatives on Prescribing Practices in Mekelle, Northern Ethiopia. PLoS One. 2016; 11(6):e0156795. PMC: 4911221. DOI: 10.1371/journal.pone.0156795. View

17.

Kravitz R . Direct-to-consumer advertising of prescription drugs. West J Med. 2000; 173(4):221-2. PMC: 1071087. DOI: 10.1136/ewjm.173.4.221. View

18.

Zetterqvist A, Merlo J, Mulinari S . Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Med. 2015; 12(2):e1001785. PMC: 4331559. DOI: 10.1371/journal.pmed.1001785. View

19.

Saito S, Mukohara K, Bito S . Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey. PLoS One. 2010; 5(8):e12193. PMC: 2921334. DOI: 10.1371/journal.pone.0012193. View

20.

Alosaimi F, Alkaabba A, Qadi M, Albahlal A, Alabdulkarim Y, Alabduljabbar M . Acceptance of pharmaceutical gifts. Variability by specialty and job rank in a Saudi healthcare setting. Saudi Med J. 2013; 34(8):854-60. View